Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
αCD45-cs21
- Development stage
- Preclinical
- Lead developer
- Massachusetts Institute of Technology
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
**αCD45-cs21** is a preclinical, CD45-targeted immunocytokine comprising an anti-CD45 immunoglobulin conjugated to cs21, a computationally stabilized murine interleukin-21 variant. CD45 binding localizes the cytokine to leukocytes following intratumoral administration, while cs21 activates interleukin-21 receptor signaling and downstream STAT3 phosphorylation in immune cells. In syngeneic B16F10 melanoma models, intratumoral αCD45-cs21 increased pSTAT3 in CD45-positive cells in tumor-draining lymph nodes and improved median survival as monotherapy; combinations with IL-12 or IL-15 showed preclinical synergy without apparent toxicity. ([jitc.bmj.com](https://jitc.bmj.com/content/13/Suppl_2/A978))
- Other names
- aCD45-cs21aCD-45-cs21aCD 45-cs21αCD45-cs21
02
Targets
PTPRC (Receptor-type tyrosine-protein phosphatase C)IL21R (Interleukin-21 receptor)
Beyond the preview
Go deeper on αCD45-cs21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on αCD45-cs21.